FI3777842T3 - Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi - Google Patents
Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi Download PDFInfo
- Publication number
- FI3777842T3 FI3777842T3 FIEP20195788.3T FI20195788T FI3777842T3 FI 3777842 T3 FI3777842 T3 FI 3777842T3 FI 20195788 T FI20195788 T FI 20195788T FI 3777842 T3 FI3777842 T3 FI 3777842T3
- Authority
- FI
- Finland
- Prior art keywords
- mini
- melatonin
- tablet
- coating
- delayed
- Prior art date
Links
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 title claims 22
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title claims 22
- 229960003987 melatonin Drugs 0.000 title claims 22
- 239000008185 minitablet Substances 0.000 title claims 9
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003826 tablet Substances 0.000 claims 14
- 229920001577 copolymer Polymers 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 239000011248 coating agent Substances 0.000 claims 7
- 238000000576 coating method Methods 0.000 claims 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 4
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 4
- 229960001021 lactose monohydrate Drugs 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009501 film coating Methods 0.000 claims 2
- 239000007888 film coating Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000009495 sugar coating Methods 0.000 claims 2
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662415014P | 2016-10-31 | 2016-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3777842T3 true FI3777842T3 (fi) | 2025-02-11 |
Family
ID=57482481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20195788.3T FI3777842T3 (fi) | 2016-10-31 | 2016-11-29 | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10722494B2 (https=) |
| EP (3) | EP3337462B1 (https=) |
| JP (1) | JP6830156B2 (https=) |
| KR (1) | KR102167190B1 (https=) |
| CN (1) | CN109922795B (https=) |
| AU (6) | AU2016426598C1 (https=) |
| CA (1) | CA3040027C (https=) |
| CY (1) | CY1123449T1 (https=) |
| DK (2) | DK3337462T3 (https=) |
| ES (2) | ES3009413T3 (https=) |
| FI (1) | FI3777842T3 (https=) |
| HR (2) | HRP20250166T1 (https=) |
| HU (2) | HUE051362T2 (https=) |
| IL (1) | IL262537B (https=) |
| LT (2) | LT3777842T (https=) |
| MX (1) | MX386987B (https=) |
| NZ (1) | NZ747702A (https=) |
| PL (2) | PL3777842T3 (https=) |
| PT (2) | PT3337462T (https=) |
| RS (2) | RS61024B1 (https=) |
| SG (1) | SG11201903829PA (https=) |
| SI (2) | SI3777842T1 (https=) |
| SM (2) | SMT202500046T1 (https=) |
| TW (1) | TWI787164B (https=) |
| WO (1) | WO2018078429A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220125733A1 (en) * | 2020-10-23 | 2022-04-28 | Atoz Pharmaceuticals Pvt Ltd | Nongranulated compressed tablets of mesalamine, and process of preparation thereof |
| KR102918707B1 (ko) * | 2020-10-26 | 2026-01-28 | 일동제약(주) | 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제 |
| CA3268494A1 (en) | 2022-10-14 | 2024-04-18 | Société des Produits Nestlé S.A. | DELAYED-RELEASE MELATONIN COMPOSITIONS |
| CN117281909A (zh) * | 2023-07-27 | 2023-12-26 | 上海长征医院 | 一种野外条件下诱导快速入睡的组合物及制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4600723A (en) | 1983-05-18 | 1986-07-15 | Monash University | Method for minimizing disturbances in circadian rhythms of bodily performance and function |
| ES2134789T3 (es) | 1991-05-09 | 1999-10-16 | Neurim Pharma 1991 | Composiciones que contienen melatonina. |
| DE69303919T2 (de) | 1992-04-07 | 1997-01-30 | Neurim Pharma 1991 | Verwendung von Melatonin zur Herstellung eines Arzneimittels zur Behandlung der gutartigen Prostatahyperplasie |
| US5449683A (en) | 1992-10-01 | 1995-09-12 | Massachussetts Institute Of Technology | Methods of inducing sleep using melatonin |
| WO1995003043A1 (en) * | 1993-07-26 | 1995-02-02 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Sustained release oral compositions containing melatonin |
| MD1716C2 (ro) * | 1995-02-01 | 2002-02-28 | Neurim Pharmaceuticals (1991) Ltd. | Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine |
| US6469044B1 (en) * | 1995-02-01 | 2002-10-22 | Neurim Pharmaceuticals (1991) Ltd. | Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies |
| FR2762513B1 (fr) * | 1997-04-23 | 2003-08-22 | Permatec Pharma Ag | Comprimes bioadhesifs |
| WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
| EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| MXPA02005783A (es) * | 2000-01-05 | 2003-10-14 | Neurim Pharma 1991 | Metodo y formulacion para el tratamiento de la resistencia a los antihipertensivos y otras afecciones asociadas. |
| US6458384B2 (en) * | 2000-02-23 | 2002-10-01 | Impetus Ag | Pharmaceutical with predetermined activity profile |
| IL144900A (en) | 2001-08-14 | 2013-12-31 | Neurim Pharma 1991 | Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs |
| IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
| KR20030016215A (ko) * | 2002-07-05 | 2003-02-26 | 뉴림 파머슈티칼스 (1991) 리미티드 | 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형 |
| EP1592453A1 (en) * | 2003-01-28 | 2005-11-09 | Collegium Pharmaceutical, Inc. | Multiparticulate compositions of milnacipran for oral administration |
| IL155666A (en) | 2003-04-29 | 2013-12-31 | Neurim Pharma 1991 | Insomnia treatment |
| CA2551637A1 (en) | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
| FR2889811B1 (fr) * | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| DE102006006532B4 (de) | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmazeutische Zubereitung |
| WO2008148015A1 (en) | 2007-05-24 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Sustained release formulation of melatonin |
| US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
| RU2488388C1 (ru) * | 2012-05-24 | 2013-07-27 | Ооо "Валента Интеллект" | Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств |
| DK2949322T3 (en) | 2014-05-28 | 2018-07-23 | Valpharma S P A | FORMULATION FOR ORAL ADMINISTRATION COMPREHENSIVE MELATONIN IN STABLE FORM AND PROCEDURE FOR PREPARING THEREOF |
-
2016
- 2016-11-29 JP JP2019519420A patent/JP6830156B2/ja active Active
- 2016-11-29 DK DK16805903.8T patent/DK3337462T3/da active
- 2016-11-29 EP EP16805903.8A patent/EP3337462B1/en active Active
- 2016-11-29 KR KR1020187035251A patent/KR102167190B1/ko active Active
- 2016-11-29 RS RS20201242A patent/RS61024B1/sr unknown
- 2016-11-29 HU HUE16805903A patent/HUE051362T2/hu unknown
- 2016-11-29 SI SI201631888T patent/SI3777842T1/sl unknown
- 2016-11-29 NZ NZ747702A patent/NZ747702A/en active IP Right Revival
- 2016-11-29 SG SG11201903829PA patent/SG11201903829PA/en unknown
- 2016-11-29 PL PL20195788.3T patent/PL3777842T3/pl unknown
- 2016-11-29 HR HRP20250166TT patent/HRP20250166T1/hr unknown
- 2016-11-29 PT PT168059038T patent/PT3337462T/pt unknown
- 2016-11-29 PL PL16805903T patent/PL3337462T3/pl unknown
- 2016-11-29 AU AU2016426598A patent/AU2016426598C1/en active Active
- 2016-11-29 WO PCT/IB2016/057190 patent/WO2018078429A1/en not_active Ceased
- 2016-11-29 LT LTEP20195788.3T patent/LT3777842T/lt unknown
- 2016-11-29 HU HUE20195788A patent/HUE070190T2/hu unknown
- 2016-11-29 CN CN201680090550.4A patent/CN109922795B/zh active Active
- 2016-11-29 MX MX2019004736A patent/MX386987B/es unknown
- 2016-11-29 ES ES20195788T patent/ES3009413T3/es active Active
- 2016-11-29 FI FIEP20195788.3T patent/FI3777842T3/fi not_active Application Discontinuation
- 2016-11-29 HR HRP20201722TT patent/HRP20201722T1/hr unknown
- 2016-11-29 PT PT201957883T patent/PT3777842T/pt unknown
- 2016-11-29 EP EP24208766.6A patent/EP4474012A3/en active Pending
- 2016-11-29 SI SI201630947T patent/SI3337462T1/sl unknown
- 2016-11-29 SM SM20250046T patent/SMT202500046T1/it unknown
- 2016-11-29 RS RS20250094A patent/RS66471B1/sr unknown
- 2016-11-29 LT LTEP16805903.8T patent/LT3337462T/lt unknown
- 2016-11-29 EP EP20195788.3A patent/EP3777842B1/en active Active
- 2016-11-29 SM SM20200575T patent/SMT202000575T1/it unknown
- 2016-11-29 ES ES16805903T patent/ES2828034T3/es active Active
- 2016-11-29 CA CA3040027A patent/CA3040027C/en active Active
- 2016-11-29 DK DK20195788.3T patent/DK3777842T3/da active
- 2016-12-26 TW TW105143159A patent/TWI787164B/zh active
-
2018
- 2018-10-24 IL IL262537A patent/IL262537B/en active IP Right Grant
- 2018-10-31 US US16/176,338 patent/US10722494B2/en active Active
-
2019
- 2019-01-24 AU AU2019200479A patent/AU2019200479B2/en active Active
- 2019-11-28 AU AU2019101470A patent/AU2019101470B4/en not_active Expired
-
2020
- 2020-06-16 US US16/902,419 patent/US10869857B2/en active Active
- 2020-10-14 CY CY20201100971T patent/CY1123449T1/el unknown
-
2021
- 2021-01-18 AU AU2021200268A patent/AU2021200268A1/en not_active Abandoned
-
2023
- 2023-03-31 AU AU2023202003A patent/AU2023202003A1/en active Pending
-
2025
- 2025-09-18 AU AU2025234204A patent/AU2025234204A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tao et al. | Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin | |
| KR101834033B1 (ko) | 주의력 결핍 장애 치료용 고체 경구 제약 조성물 | |
| FI3902547T3 (fi) | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa | |
| BR112019025286A2 (pt) | Métodos e composições para tratamento de sonolência excessiva | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| FI3777842T3 (fi) | Melatoniinin minitabletteja ja menetelmä niiden valmistamiseksi | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| FI4212152T3 (fi) | Sakubitriili-valsartaaniannostusohjelma kroonisen systolisen sydämen vajaatoiminnan hoitoon | |
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| BRPI0716436B8 (pt) | sistema de liberação controlada e método para fabricação do mesmo | |
| RU2017112308A (ru) | Композиции и способы для лечения бессонницы | |
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| WO2012173581A4 (en) | Thiocolchicoside, etodolac and famotidine combinations | |
| JP7219898B2 (ja) | アルカリ性化剤による血液浄化 | |
| JP2019533672A5 (https=) | ||
| RU2018104691A (ru) | Композиции с модифицированным высвобождением ницерголина | |
| Sanchez-Delgado et al. | Role of rifaximin in the treatment of hepatic encephalopathy | |
| CN106138019A (zh) | Gpr35受体激动剂及其应用 | |
| JP2503571B2 (ja) | 脳循環代謝改善剤 | |
| Moore et al. | Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers | |
| CN111065389A (zh) | 治疗自身免疫性微脉管疾病的方法 | |
| US20200297659A1 (en) | Methods of diagnosis and treatment involving nitrite | |
| RU2013124994A (ru) | КОМБИНАЦИЯ БЕВАЦИЗУМАБА И 2,2-ДИМЕТИЛ-N-((S)-6-ОКСО-6,7-ДИГИДРО-5Н-ДИБЕНЗО[b,d]АЗЕПИН-7-ИЛ)-N'-(2,2,3,3,3-ПЕНТАФТОР-ПРОПИЛ)-МАЛОНАМИДА ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| NZ782840B2 (en) | Melatonin mini-tablets and method of manufacturing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application lapsed |